Bone Marrow-Derived Progenitor Cells Augment Venous Remodeling in a Mouse Dorsal Skinfold Chamber Model by Doyle, Megan E. et al.
Bone Marrow-Derived Progenitor Cells Augment Venous
Remodeling in a Mouse Dorsal Skinfold Chamber Model
Megan E. Doyle*, Jeffrey P. Perley, Thomas C. Skalak
Department of Biomedical Engineering, University of Virginia, Charlottesville, Virginia, United States of America
Abstract
The delivery of bone marrow-derived cells (BMDCs) has been widely used to stimulate angiogenesis and arteriogenesis. We
identified a progenitor-enriched subpopulation of BMDCs that is able to augment venular remodeling, a generally
unexplored area in microvascular research. Two populations of BMDCs, whole bone marrow (WBM) and Lin
2/Sca-1
+
progenitor cells, were encapsulated in sodium alginate and delivered to a mouse dorsal skinfold chamber model. Upon
observation that encapsulated Sca-1
+ progenitor cells enhance venular remodeling, the cells and tissue were analyzed on
structural and molecular levels. Venule walls were thickened and contained more nuclei after Sca-1
+ progenitor cell delivery.
In addition, progenitors expressed mRNA transcript levels of chemokine (C-X-C motif) ligand 2 (CXCL2) and interferon
gamma (IFNc) that are over 5-fold higher compared to WBM. Tissues that received progenitors expressed significantly
higher protein levels of vascular endothelial growth factor (VEGF), monocyte chemotactic protein-1 (MCP-1), and platelet
derived growth factor-BB (PDGF-BB) compared to tissues that received an alginate control construct. Nine days following
cell delivery, tissue from progenitor recipients contained 39% more CD45
+ leukocytes, suggesting that these cells may
enhance venular remodeling through the modulation of the local immune environment. Results show that different BMDC
populations elicit different microvascular responses. In this model, Sca-1
+ progenitor cell-derived CXCL2 and IFNc may
mediate venule enlargement via modulation of the local inflammatory environment.
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Introduction
Microvascular adaptations occur through the processes of
angiogenesis, arteriogenesis, and venule remodeling in response
to both physiological and pathological stimuli. Understanding how
the microvasculature responds to external stimuli is critical if these
processes are to be manipulated in the treatment of disease.
Delivery of cells, specifically bone marrow-derived cells (BMDCs),
is actively investigated as a means to stimulate the growth of new
vasculature or enlargement of pre-existing vessels [1,2]. The
known effects of BMDCs on angiogenesis and arteriogenesis in the
microcirculation supports the use of these cells for therapeutic
benefit [1,3,4,5]. The impact of these cells on the venular side of
these microvascular networks, however, is less established.
The local delivery of BMDCs has become a widely investigated
tool for the treatment of ischemic disease including peripheral
limb ischemia and myocardial infarction [6,7,8,9]. Additionally,
delivery of BMDCs is also being investigated with regard to
acceleration of wound healing, to specifically translate to clinical
applications where diseases like diabetes may impede the body’s
ability to repair itself [10,11,12]. Whole bone marrow (WBM),
bone marrow mononuclear cells (BM-MNCs), and purified groups
of bone marrow-derived progenitor cells such as hematopoietic
stem cells (HSCs), endothelial progenitor cells (EPCs) and
mesenchymal stem cells (MSCs) have all been used to stimulate
the restoration of blood flow in ischemic tissues via stimulation of
new capillary growth or collateral vessel enlargement [13,14,
15,16]. Exogenous BMDCs are most often delivered to tissue via
local cell injection, but some studies have used implantable
matrices to deliver these cells in an effort to improve cell retention
in the tissue [17,18].
Once delivered, BMDCs have been shown to augment
remodeling in tissues through a variety of mechanisms including
transdifferentiation, cell fusion, support via paracrine mechanisms,
and modulation of endogenous progenitor populations in the
tissue [2,19,20,21,22,23]. Recent work also shows that cytokines
released from BMDCs can modulate inflammatory function by
enhancing the recruitment of circulating leukocytes to sites of
exogenous cell delivery [24,25]. Upon arrival in the tissue, these
inflammatory cells are also able to modulate remodeling via
growth factor production.
In this study, the in vivo mouse dorsal window chamber model
was used in conjunction with a variety of experimental techniques
including intravital image analysis, immunohistochemistry, gene
expression profiling, and protein level quantification to evaluate
microvascular remodeling responses on both structural and
molecular levels. The dorsal skinfold window chamber enables
chronic observation of the microcirculatory process of wound
healing. Specifically, this model allows for repeat analysis of
remodeling vasculature and allows for the application of cells
directly to the surface of the remodeling vasculature.
Two populations of BMDCs were compared with regard to
their ability to affect microvascular remodeling. Whole bone
marrow (WBM) and a Lin
2/Sca-1
+ subfraction of bone marrow
PLoS ONE | www.plosone.org 1 February 2012 | Volume 7 | Issue 2 | e32815(Sca-1
+ progenitor cells) were chosen to specifically represent two
main components of the adult bone marrow: the mature
inflammatory cells and the undifferentiated progenitor cells. The
Lin
2/Sca-1
+ subpopulation of cells includes a majority of the
aforementioned progenitor subsets including HSCs, EPCs, and
MSCs.
Cell encapsulation in sodium alginate was used as a delivery
method because it allows for cells to be placed in close proximity to
the remodeling microvessels and can help maintain the presence of
delivered cells in the tissue since the internal structure of the gel
inhibits mobility of the cell population, limiting cell migration out
of the porous matrix [26,27].
Upon initial observation that Sca-1
+ progenitor cells encapsu-
lated in sodium alginate enhance venular remodeling, we sought to
investigate this phenomenon further by evaluating how and why
venules enlarge in response to these cells. Analysis of gene
expression, protein levels, and immunohistochemistry have
enabled us to hypothesize a putative mechanism by which these
delivered cells are able to augment venular remodeling in the
dorsal skinfold chamber model.
Methods
Ethics Statement
The following animal procedures were performed in compli-
ance with the US Department of Health and Human Services
Guide for the Care and use of Laboratory Animals and were
approved by the Animal Care and Use Committee of the
University of Virginia under protocol number 3467.
Dorsal Skinfold Window Chamber
C57Bl/6 male mice between 24 and 28 grams were anesthe-
tized with an intraperitoneal injection of ketamine (0.03 mL),
xylazine (0.015 mL), and atropine (0.005 mL) diluted in 0.2 mL of
saline. Under sterile conditions, a circular section 12 mm in
diameter was surgically excised exposing the microcirculation
within the hypodermis. A window chamber was then surgically
implanted around the dissected circle of tissue and covered with a
round coverglass. Mice were allowed 24 hours to recover from
surgery before BMDC implantation.
Bone Marrow-Derived Cell Isolation and Encapsulation
Bone marrow was isolated from the femur, tibia, and hip bone
in each hindlimb of 25–30 g male C57Bl/6 mice. Bones were
ground in a mortar and pestle in Phosphate Buffered Saline (PBS)
with 2% fetal bovine serum (FBS) and filtered through a 100 mm
cell strainer (BD). The WBM solution was centrifuged and
resuspended in sodium alginate solution for encapsulation, or
PBS with 2% FBS and 5% Normal Rat Serum for progenitor cell
separation. The Lin
2/Sca-1
+ fraction of the WBM was isolated
using magnetic isolation using both hematopoietic progenitor cell
enrichment and biotin selection kits (Stem Cell Technologies).
WBM or Lin
2/Sca-1
+ cells were mixed in a 1.5% w/v alginate
solution and aspirated into 102 mmol/L CaCl2 solution (in
saline). Newly formed alginate beads (1 mm) contained 2610
4
cells. Prior to bead implantation, cell viability was checked with a
live/dead assay (Invitrogen). Once viability over 80% was
verified, one 1 mm bead was carefully placed in the center of
each dorsal skinfold chamber 24 hours following surgery (Day 1).
Table 1 outlines the experimental groups used for this portion of
the study.
Encapsulated Cell Delivery and Intravital Image
Acquisition
At each time point, mice were anesthetized using 2.5%
isoflurane. Prior to imaging, the glass coverslip was removed from
the window and adenosine (10
24 M) in Ringer’s solution was
topically applied to the tissue for ten minutes to maximally dilate
vessels in the chamber. The entire window was imaged at 46
magnification on days 1, 4, 7 and 10, and montages were
constructed using Adobe CS2 image processing software. Image J
software (NIH) was used to measure all vascular metrics. Vessels
are distinguished as arterioles or venules based on blood flow
direction at the time of imaging. In reconstructed images,
diameters were measured at a distance two vessel diameters away
from vessel branch points. A measure of blood column width was
made for every vessel and vessel branch that could be
distinguished at all timepoints. Starting vessel diameters for
arterioles and venules were divided into two bins, above and
below the mean (30 um and 57 um, respectively), so that the
responses of comparably sized vessels were compared to one
another.
Tissue Harvest and Immunohistological Staining
Following image acquisition on day 10, window chamber tissues
were perfusion fixed, harvested, and embedded for frozen
sectioning as previously described [28]. Embedded tissues were
sectioned at a thickness of 15 mm. Some slides were stained with
Hematoxylin and Eosin (H&E) while others were labeled with
immunofluorescent antibodies. Slides were labeled with 1:200
smooth muscle a-actin 1A4 (Sigma), 1:50 biotin conjugated CD45
(BD Pharmingen), or 1:20 MCP-1 (eBioscience). Slides were then
mounted with VectaStain hard mount containing DAPI for
labeling of cell nuclei (Vector Labs).
Fluorescently labeled specimens were examined using confocal
microscopy. All measurements were made in a blinded fashion.
Each section stained for CD45 was imaged with a consistent gain-
setting at 206in three areas of the section. The number of CD45
positive cells and total cell nuclei were manually counted for each
area. Additionally, the number of CD45 positive cells and number
of total nuclei were manually counted at 206 magnification in
large venules within the SM a-actin positive medial walls, and
10 mm beyond the medial layer to account for inflammatory cells
present in the adventitia. In these images, the luminal circumfer-
ence of SM a-actin expression was used to normalize the number
of CD45
+ cells per vessel. Whole H&E labeled sections were
imaged at 506magnification. Venules were analyzed for wall area
and number of nuclei per venule. These metrics were normalized
by vessel luminal or inner circumference since imperfect cross-
sections prevent normalization by vessel diameter.
Table 1. Bone Marrow-Derived Cell Delivery and Control
Groups.
Treatment n
WBM 15
Sca-1+Progenitors 15
Vehicle 11
Untreated 11
doi:10.1371/journal.pone.0032815.t001
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+ Progenitors
Real time reverse transcriptase PCR (RT-RTPCR) was
conducted using a PCR array to analyze the expression of a
focused panel of genes related to the promotion and inhibition of
angiogenesis. The array was used to profile the gene expression of
84 growth factors and inhibitors in isolated WBM and Sca-1
+
progenitor cells. WBM was treated as a control cell type for
comparison with the progenitors. A conservative threshold of five-
fold was set to identify genes that are expressed at substantially
different levels among the two cell types. RNA was extracted from
WBM and Lin
2/Sca-1
+ cells following cell separation using
TRIzol (Invitrogen) and retrotranscribed using a RT
2 First Strand
Kit (SABiosciences). PCR was performed using the Angiogenic
Growth Factors and Angiogenesis Inhibitors RT
2 Profiler PCR
Array and RT
2 SYBR Green/Fluorescein qPCR Master Mix
(SABiosciences). Gene expression levels for WBM and Lin
2/Sca-
1
+ cells were calculated with the DDCt method with normalization
to the average expression level of five housekeeping genes. Then,
relative differences in gene expression between WBM and Sca-1
+
progenitors were evaluated. A positive value indicates elevated
gene expression in progenitor cells relative to WBM. PCR arrays
were run twice for each cell population using RNA isolates from
two different cell separation procedures. Each Sca-1
+ progenitor
RNA sample was prepared with cells harvested from eight
animals, and each WBM RNA sample was prepared with cells
harvested from four animals.
Quantification of Cytokine Expression in Mouse Window
Chamber Tissues
Following image acquisition on day 10, animals were
euthanized with pentobarbital sodium (60 mg/kg i.p.). At days
1, 4 and 10 the window area was dissected away from the dorsal
area and homogenized in RIPA buffer (Sigma) containing
protease and phosphatase inhibitors (Roche). Prior to performing
ELISAs (R&D Systems), total protein levels in all samples were
determined using a protein assay with a bovine serum albumin
standard (Bio-Rad).
Statistical Analysis
One-Way Analysis of Variance (ANOVA) was used in
experiments where multiple groups were present. If ANOVA
analysis determines a difference between groups, the Student-
Newman-Keuls method was used as a post hoc test to determine
significance below p=0.05. For experiments where only two
groups were present, comparisons were made using Student t-tests.
All statistical analysis was performed using SigmaStat software and
values are presented +/2 SE.
Results
Sca-1
+ Progenitors Cells Augment Venular Remodeling
The mouse dorsal skinfold window chamber model was used to
evaluate the impact of delivered BMDCs on microvascular
remodeling (Figure 1). Vessels within the skinfold chamber
underwent angiogenesis, arteriogenesis, and venular remodeling
over time, occurring as a result of the inflammatory stimulus of the
surgery alone (Figure 1B).
In arterioles with starting diameters below the mean, encapsu-
lated WBM elicited an arteriogenic response in the chamber that
exceeded the response in both encapsulated Sca-1
+ progenitor
recipients and alginate control construct recipients (Figure 2A).
This result supports the hypothesis that WBM can have an
arteriogenic impact on remodeling vasculature. However, in this
model, the arteriogenic response observed in the smaller arterioles
does not exceed that of the untreated control (Figure 2A).
BMDCs had a significant impact on venular remodeling
(Figure 2C), specifically Sca-1
+ progenitor cells on the larger
venules in the tissue (Figure 2D). In venules with starting
diameters above the mean, encapsulated Sca-1
+ progenitor cell
recipients underwent diameter changes from Day 1 to Day 10 that
surpassed both alginate and untreated controls by 81% and 93%,
respectively (Figure 2D).
These results suggest a previously undiscovered role for Sca-1
+
progenitor cells in venular remodeling. We sought to investigate
this observation with further analysis into the structural and
molecular adaptations taking place in the tissue in response to the
Sca-1
+ progenitor cell delivery.
Figure 1. Microvascular Remodeling in the Mouse Dorsal Window Chamber. (A) Representative montage of the window chamber at 4x. (B)
Example ten day time course of the remodeling network. Arterioles and venules enlarge slightly from days one to four. Diameter increases and
angiogenic remodeling is accelerated from days 4 to 10.
doi:10.1371/journal.pone.0032815.g001
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+ Progenitor Cells
H&E histological analysis was used to assess venous structural
adaptations in animals that received encapsulated Sca-1
+ progen-
itor cells or alginate control constructs (Figure 3).
Final venule wall area was 49% larger in the animals that
received encapsulated Sca-1
+ progenitor cells (Figure 3A).
Additionally, there were more cell nuclei in the walls surrounding
venules in progenitor recipients (Figure 3B). However, the
number of cell nuclei per square micron of venule wall area was
comparable among both groups (Figure 3C). Since the number of
cells per area in the vessel walls was comparable between venules
from animals that received encapsulated progenitor cells and
animals that received only an alginate control construct,
immunohistochemical analysis was used to evaluate whether the
thickened walls were a result of increased inflammatory cell
Figure 2. Encapsulated Cells’ Impact on Arteriole and Venule Diameters over 10 Days. (A) Average absolute arteriole diameter change
over ten days in vessels with starting diameter below the mean. (B) Average absolute arteriole diameter change over ten days in vessels with starting
diameter above the mean. (C) Average absolute venule diameter change over ten days in vessels with starting diameter below the mean. (D) Average
absolute venule diameter change over ten days in vessels with starting diameter above the mean. * indicates p,0.05 as calculated by ANOVA. Data
are means +/2 S.E.
doi:10.1371/journal.pone.0032815.g002
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that the number of CD45
+ inflammatory cells in the venule walls
was also comparable in both groups (Figure 3D).
Sca-1
+ Progenitor Cells Express High Levels of
Angiogenic Activator mRNA
Encapsulated Sca-1
+ progenitor cells were able to elicit a strong
venular remodeling response in the dorsal skinfold chamber. To
achieve better mechanistic understanding of the role that these
cells play in the remodeling process, potential molecular mediators
were evaluated with a PCR array designed to analyze the
expression of a focused panel of genes related to the promotion
and inhibition of angiogenesis.
Of the 84 genes compared in multiple isolations of both cell
types, two were reproducibly expressed over five-fold higher in
WBM and two were reproducibly expressed over five-fold higher
in the Sca-1
+ progenitors (Figure 4).
Of these, mRNA transcripts of fibroblast growth factor-2 (FGF-
2) and fibronectin-1 (Fn-1) were expressed at much higher levels in
WBM cells compared to Sca-1
+ progenitors (5.05 fold and 18.39
fold higher, respectively). Two factors, interferon gamma (IFNc)
and chemokine (C-X-C motif) ligand-2 (CXCL2), contained
transcripts at much higher levels in the Sca-1
+ progenitors
(15.44 fold and 91.39 fold higher, respectively).
Next, gene expression was analyzed relative to a negative
threshold cycle number. Genes that amplify at cycle numbers
above 35 were considered non-amplifying, indicating very low to
no expression (Figure 5). The red box indicates the range of
cycle numbers where gene expression is considered very low, and
the green box shows the range where genes would be considered
early amplifying and very abundant. In both cell types, FGF-2
amplified at a cycle number that is indicative of very low genetic
expression. In WBM, IFNc and CXCL2 both amplified at cycle
numbers that signify very low expression of these cytokines.
However, in Sca-1
+ progenitors both of these genes amplified at
cycle numbers that are indicative of high genetic expression.
Fibronectin-1 did not appear to be a low amplifying gene in
either cell type, although its expression was significantly higher in
WBM cells.
Dorsal Tissues Express Elevated Vasculogenic Cytokines
in Response to Sca-1
+ Progenitor Cell Delivery
ELISAs were used to determine the tissue levels of vascular
endothelial growth factor (VEGF), platelet-derived growth factor-
BB (PDGF-BB), monocyte chemotactic protein-1 (MCP-1),
epidermal growth factor (EGF), tumor necrosis factor-a (TNF-a),
and chemokine (C-X-C motif) ligand 2 (CXCL2/MIP-2) within
whole window chamber tissues. These proteins were chosen
because previous work suggests that they could play a role in
venular remodeling [29,30,31,32,33,34,35,36,37]. The expression
of each of these factors can also be elicited by progenitor cell
secretion of CXCL2 or IFNc [38,39].
Elevated expression of VEGF and MCP-1 over that of quiescent
tissue was observed at Day 1 and is likely a byproduct of the initial
inflammatory response to the surgical implantation of the dorsal
skinfold chamber. In addition, protein levels of VEGF, MCP-1,
and PDGF-BB were all significantly elevated in progenitor cell
treated animals at Day 4 (Figure 6). VEGF protein expression in
Sca-1
+ progenitor recipients was 1.7 fold higher (Figure 6A), and
MCP-1 and PDGF-BB protein expression in Sca-1
+ progenitor
recipients was 1.4 fold higher relative to alginate control animals
(Figure 6B,C). Expression of EGF, TNF-a, and CXCL2/MIP-2
was comparable between Sca-1
+ progenitor and alginate control-
treated tissues (data not shown).
Figure 3. Structural Analysis and Cellular Composition of Remodeled Venules. (A) Average venule wall area per micron inner luminal
circumference. (B) Number of nuclei in venule wall per micron inner luminal circumference. (C) Number of cell nuclei per square micron venule wall
area. (D) Number of CD45 positive cells per micron luminal actin length. * indicates p,0.05 as calculated by Student’s t-test. Data are means +/2 S.E.
doi:10.1371/journal.pone.0032815.g003
Impact of Progenitor Cells on Venous Remodeling
PLoS ONE | www.plosone.org 5 February 2012 | Volume 7 | Issue 2 | e32815Delivery of Encapsulated Sca-1
+ Cells Elevates the
Number of Tissue Resident Inflammatory Cells
Next, to evaluate whether inflammatory cell recruitment could
be playing a role in the observed venular remodeling in response
to Sca-1
+ progenitor cells, tissue sections from animals that
received either encapsulated Sca-1
+ progenitors or alginate-only
constructs were analyzed for differences in CD45
+ cell density
(Figure 7A,B).
Figure 5. Comparison of Negative Threshold to Cycle Number of Gene Amplification for WBM and Sca-1
+ Progenitors. Fn-1, IFN c,
and CXCL2 amplify at cycles significantly below the negative threshold in both WBM and Sca-1
+ progenitors, while FGF-2 amplifies at a cycle number
indicative of low genetic expression in both cell types. * indicates p,0.05 as calculated by ANOVA. Data are means +/2 S.E.
doi:10.1371/journal.pone.0032815.g005
Figure 4. Statistical Analysis of mRNA Transcripts from Multiple Cell Isolations. Fold differences between mRNA transcript levels were
compared for two isolations of the WBM and progenitor populations. The black line indicates no fold-change in gene expression. Pink lines indicate a
five-fold change in gene expression threshold. The blue line indicates a threshold of statistical significance indicated by p,0.05 as calculated by
Student’s t-test.
doi:10.1371/journal.pone.0032815.g004
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+ cells in the window chamber
tissue of Sca-1
+ progenitor cell recipients was elevated compared
to alginate control recipients (Figure 7A). These new inflamma-
tory cells appear to make up a significant contribution to the dorsal
tissue since the percentage of CD45
+ cells to total cells in the tissue
is also significantly elevated in the Sca-1
+ cell recipients
(Figure 7B).
The elevated number of CD45
+ cells in the animals that
received Sca-1
+ progenitors suggests that these cells could be
primary mediators of the observed venular enlargement and that
they accomplish this through the production of multiple growth
factors including VEGF, MCP-1, and PDGF-BB. In order for the
CD45
+ cells to accomplish this, however, they must be able to
produce these growth factors within the window chamber tissue.
Therefore, immunohistochemical analysis was used to confirm
that the CD45
+ cells are able to produce MCP-1 in the chamber.
To analyze MCP-1 antibody expression in these cells, serial Z-
sections were taken at 5 mm intervals to confirm protein expression
to be localized within CD45
+ cells (Figure 8). The detected
presence of MCP-1 within the CD45
+ cells supports the hypothesis
that they are capable of contributing to the elevated levels of
VEGF, MCP-1, and PDGF-BB measured within the chamber at
Day 4 (Figure 6).
Discussion
Results of this study suggest that delivered BMDCs can
influence venular remodeling and identify possible molecular
mechanisms by which progenitor-enriched BMDCs are able to
elicit venular structural adaptations. Previous work has identified
venular remodeling in response to electrical stimulation, vein
grafting, hypertension, and allogenic endothelial cell matrix
Figure 6. Enhanced Protein Expression of VEGF, MCP-1, and PDGF-BB in Dorsal Skinfold Chambers. (A) Delivery of encapsulated Sca-1
+
progenitor cells elevated VEGF protein expression in dorsal tissue at day 4. (B) Delivery of encapsulated Sca-1
+ progenitor cells elevated MCP-1
protein expression in dorsal tissue at day 4. (C) Delivery of encapsulated Sca-1
+ progenitor cells elevated PDGF-BB protein expression in dorsal tissue
at day 4. * indicates p,0.05 as calculated by ANOVA. Data are means +/2 S.E.
doi:10.1371/journal.pone.0032815.g006
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eling in response to BMDC delivery is either not quantified or is
grouped together with vessel enlargements on the arteriole side of
the network. Observation of venular enlargement in response to
delivered Sca-1
+ progenitor cells is not entirely surprising since
similar populations of cells have been shown to promote enhanced
collateralization in an ischemic hindlimb model [6,19]. Endothe-
lium and smooth muscle on venules, like their arteriolar
counterparts, have the ability to modulate their response to a
variety of stimuli [40,41,42,43,44].
In response to biomechanical and biochemical stimuli, venules
can alter their structure by increasing their luminal diameter, and
exhibit increases in inflammatory and smooth muscle cell wall
investment [41,45]. We observed that in response to Sca-1
+
progenitor cell delivery the walls of these enlarged venules were
thickened and contained increased numbers of cell nuclei.
However, the number of cells per area in the vessel walls was
comparable between venules from animals that received encap-
sulated progenitor cells and animals that received only an alginate
control construct, suggesting that the thickened walls are a result of
increased cell investment. While the number of CD45
+ inflam-
matory cells was elevated in the tissue surrounding the vessels, the
number of these cells in or closely associated with the venule walls
was comparable in both groups. Thus, the cells responsible for
increasing venule wall thickness in Sca-1
+ progenitor cell recipients
may be mural cells like smooth muscle or pericytes. This is not
surprising since in progenitor cell-treated tissues we quantified an
elevated level of PDGF-BB, a cytokine that upregulates the
proliferation of smooth muscle and pericytes [46]. Previous work
has shown that in the mouse dorsal skinfold window chamber
model, venule structural diameter is increased in response to
PDGF-BB growth factor delivery [31]. Thus, PDGF-BB may be a
primary mediator of venular structural remodeling in this model.
We have shown that the Sca-1
+ subfraction of bone marrow is
sufficient in stimulating venule remodeling in the skinfold
chamber, and we have observed that WBM does not elicit the
same effect in the tissue. To begin to understand why these two cell
populations differ with regard to enhancing venular remodeling,
we sought to identify differences in the expression of angiogenic
cytokines among the two populations. In keeping with other
studies of BMDCs, gene expression analysis of these populations
revealed elevated expression of many growth factors and
angiogenic cytokines that are known to modulate inflammatory
and angiogenic processes [2,47,48,49,50]. However, analysis of
Figure 7. Inflammatory Cell Recruitment in Sca-1
+ Progenitor Cell Recipients and Control Animals. (A) Number of CD45 positive cells per
square micron skinfold chamber tissue. (B) Total percentage of CD45 expressing cells in the skinfold chamber tissue. * indicates p,0.05 as calculated
by ANOVA. Data are means +/2 S.E.
doi:10.1371/journal.pone.0032815.g007
Figure 8. MCP-1 Expression in CD45
+ Cells in Sca-1
+ Progenitor
Cell Recipients. (A–C) CD45 expression in a cell 5 microns above and
below the focal plane. (D–F) MCP-1 expression in a cell 5 microns above
and below the focal plane. (G–H) Merged CD45 and MCP-1 expression
in a cell 5 microns above and below the focal plane. (Scale bar, 5 mm).
doi:10.1371/journal.pone.0032815.g008
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were very highly expressed in the Sca-1
+ progenitors compared to
WBM. Thus, we believe that in this model these two cytokines
may be responsible for modulating the dynamic process that
ultimately results in enhanced venular remodeling. By integrating
this information with data from other published studies, we can
begin to construct a possible mechanism by which these cells
elevate tissue expression of VEGF, PDGF-BB, and MCP-1 and
enhance venular remodeling (Figure 9).
Past research has shown that IFNc can act directly on vascular
smooth muscle to stimulate proliferation and remodeling [51]. This
factor can also activate tissue resident monocytes that are able to
increase local expression of VEGF and PDGF-BB as well as recruit
additional activated monocytes to the dorsal tissue, via MCP-1
expression [39]. Studies have demonstrated that the stimulation of
neutrophils with CXCL2 leads to their recruitment and release of
biologically active VEGF-A that initiates an angiogenic cascade
within the affected tissue [38]. Elevated concentration of VEGF can
stimulate vasodilation by acting on endothelial receptors to increase
nitric oxide production by endothelial cells [52]. Nitric oxide could
then relax smooth muscle on the venules, increasing circumferential
wall stress. This stimulus has been linked to arteriole remodeling
and might impact venules similarly [53,54]. Finally, elevated levels
of PDGF-BB can enhance pericyte and smooth muscle cell
migration and proliferation that may lead to increased mural cell
investment in the venular walls [46].
Our observation of elevated transcript levels of CXCL2 and
IFNc in Sca-1
+ progenitor cells and our understanding of the
mechanisms by which these factors can lead to the remodeling of
vessels led us to hypothesize that delivered Sca-1
+ progenitors are
able to modulate the local inflammatory response within the dorsal
tissue. It is possible that the delivered Sca-1
+ progenitor cell
production of CXCL2 and IFNc is not large enough to elevate
whole tissue levels of either factor since the number of delivered
cells is very small when compared to the total number of cells
within the dorsal skinfold chamber. However, growth factor
secreted from delivered cells may be substantial enough to impact
native cells in the skinfold chamber local to the implanted cell/
alginate construct. Once these native cells become activated, they
can elevate their production of growth factors and adhesion
molecules, including VEGF, MCP-1 and PDGF. The increased
production of these factors can also stimulate the recruitment of
additional inflammatory cells to the tissue. These inflammatory
cells can contribute to cytokine production in the dorsal tissue and
additional cell recruitment. This positive feedback process would
lead to a significant elevation of inflammatory cells and growth
factor production in the tissues that received progenitor cells.
The possibility of inflammatory cell modulation by the delivered
Sca-1
+ progenitors was evaluated by quantifying the number of
CD45
+ cells in the tissue at day 10. Compared to control tissues,
Sca-1
+ progenitor cells increased inflammatory cell presence in the
tissue by 39%. We also confirmed that these CD45
+ cells are a
potent source of MCP-1 by showing cellular expression of this
factor in tissue from Sca-1
+ progenitor recipients. In addition to
MCP-1, these cells are also capable of producing high levels of
VEGF and PDGF-BB [55,56]. The idea that delivered cells may
affect microvascular remodeling by modulating the local inflam-
matory environment is a concept that is garnering more attention.
Recent work has shown that transplanted MAPC-derived
progenitor cells increase tissue levels of SDF-1, CXCL2, and
MCP-1 and that these cells elevate the recruitment of CD11b
+
cells to the ischemic hindlimb [24].
Figure 9. Proposed Mechanism of Venular Remodeling in Response to Sca-1
+ Progenitor Cells. Processes by which CXCL2 and IFNc
derived from delivered Sca-1
+ progenitor cells may stimulate the remodeling of venules in the dorsal skinfold window chamber. Boxes highlight
processes that have led to venular structural adaptation.
doi:10.1371/journal.pone.0032815.g009
Impact of Progenitor Cells on Venous Remodeling
PLoS ONE | www.plosone.org 9 February 2012 | Volume 7 | Issue 2 | e32815Overall, this study provides new information regarding
molecular regulation in the still under-explored area of venular
remodeling and provides insight into the complex interactions
between transplanted, local inflammatory, and vascular cells
within a remodeling tissue. Understanding these behaviors is
critical for successful implementation of cell therapy in the clinical
setting.
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